Sunday, October 03, 2010 7:55:29 PM
The problem with studying viruses preclinically, is there is almost no human surrogate. Humans have complex immune systems. The only good surrogates are chimps, and even those are not perfect. One chimp can cost hundreds of thousands, unfortunately--these research tools are only available to the largest pharmaceutical companies. Things like viral kinetics, antibody response, adaptive immunity - they're not well replicated in mice.
Witness the confusion in the hepatitis world (NNVC is notably absent from this disease). There is a preclinical assay, "Replicon", which drug companies use to determine efficacy without running expensive chimp studies. Replicon isn't that useful because drugs are metabolized in humans differently from in vivo experiments. This is where ADME comes to play.
Anyway, the point is preclinical virus development is a waste of time until you see human results. NNVC still hasn't filed an IND so, so much for that. It is possible that something likes rabies or dengue has an applicable model since it is a fast killing virus. Having said that, I just realized these treatments are likely going to be intravenous only, so some part of ADME argument is moot--but then so is some of the commercial oppportunity (most antivirals are oral).
Recent NNVC News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM